X0206 3 2019-10-10 0 0001706431 Vir Biotechnology, Inc. VIR 0001782338 SVF Endurance (Cayman) Ltd C/O WALKERS CORP LTD CAYMAN CORP CENTRE 27 HOSPITAL ROAD GEORGETOWN, GRAND CAYMAN E9 KY1-9008 CAYMAN ISLANDS 0 0 1 0 0001731509 SB INVESTMENT ADVISERS (UK) LTD 69 GROSVENOR STREET LONDON X0 W1K 3JW UNITED KINGDOM 0 0 1 0 0001755143 SOFTBANK VISION FUND (AIV M1) L.P. 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 0 0 1 0 Series A-1 Convertible Preferred Stock Common Stock 15555555 I See Footnote Series B Convertible Preferred Stock Common Stock 6111111 I See Footnote The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock are each convertible into Vir Biotechnology, Inc. common stock, have no expiration date and will convert into common stock automatically upon completion of the issuer's initial public offering. SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. SBIA UK is wholly owned by SoftBank Group Corp. /s/ Karen Ellerbe, Director of SVF Endurance (Cayman) Limited 2019-10-10 /s/ Brian Wheeler, General Counsel of SB Investment Advisers (UK) Limited, manager of SoftBank Vision Fund (AIV M1) L.P. 2019-10-10 /s/ Brian Wheeler, General Counsel of SB Investment Advisers (UK) Limited 2019-10-10